Clinical Trial Update: Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy [Phase 3]

View source ↗

Summary

Phase 3 trial update indicating completion of a study evaluating octreotide acetate formulated in microspheres for diabetic retinopathy, sponsored by Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Retinopathy

Drugs mentioned

• Octreotide acetate in microspheres (octreotide acetate)

Snippet

Sponsor: Novartis | Conditions: Diabetic Retinopathy | Phase 3 | Status: COMPLETED